HLA-A and familial pancreatic carcinoma: We investigated the mesothelin-derived epitope peptide restricted to HLA-A*2402 that can induce peptide-specific cytotoxic T lymphocytes (CTLs) for possible use in peptide-based immunotherapies for patients with HLA-A* 2402-positive pancreatic cancer.